OTCMKTS:GNMSF Genmab A/S Q1 2025 Earnings Results & Report $515.00 -0.53 (-0.10%) As of 09:31 AM Eastern Genmab A/S beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of $3.05 versus the $1.88 consensus estimate, while revenue of $765.14 million topped the $761.09 million estimate by $4.05 million. Research:ProfileEarnings History Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market Opens Genmab A/S EPS ResultsActual EPS$3.05Consensus EPS $1.88Beat/MissBeat by +$1.17One Year Ago EPSN/AEPS Beat Rate4 of last 5 quartersGenmab A/S Revenue ResultsActual Revenue$765.14 millionExpected Revenue$761.09 millionBeat/MissBeat by +$4.05 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Genmab A/S Q1 2025 Earnings FAQ Did Genmab A/S beat earnings estimates for Q1 2025? Genmab A/S (OTCMKTS:GNMSF) reported earnings of $3.05 per share for Q1 2025, beating the consensus estimate of $1.88. The report was announced on Thursday, May 8, 2025. What was Genmab A/S' revenue for Q1 2025? Genmab A/S reported revenue of $765.14 million for Q1 2025, against a consensus estimate of $761.09 million. Genmab A/S Earnings HeadlinesGenmab Files Articles of Association Dated November 10November 12, 2026 | tipranks.comGenmab Reports November 10 Executive Share SalesNovember 12, 2026 | tipranks.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 17 at 1:00 AM | Digest Publishing (Ad)Genmab Reports 22% Revenue Growth as Phase 3 Results Strengthen Oncology PortfolioNovember 5, 2026 | tipranks.comGenmab Gains After Phase 3 Ovarian Cancer Win for Rina-SOctober 23, 2026 | quiverquant.comQGenmab Grants Restricted Stock Units to Board After Extraordinary General MeetingOctober 7, 2026 | tipranks.comSee More Genmab A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email. Email Address About Genmab A/SGenmab A/S (OTCMKTS:GNMSF) is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on treatments for cancer and other serious diseases. The company uses its antibody technologies, including DuoBody and HexaBody, to develop therapeutic candidates and works with pharmaceutical partners to advance and commercialize medicines. Products developed through Genmab programs include Darzalex, Tecvayli, Epkinly/Tepkinly and Rybrevant, which are marketed through partnerships. Genmab conducts research and development internationally, with operations in Europe, North America and Asia. The company is led by President and Chief Executive Officer Jan van de Winkel, who co-founded Genmab.View Genmab A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.